Skip to main content

19-10-2021 | Ankylosing spondylitis | News


Tofacitinib receives EMA support for ankylosing spondylitis

Shreeya Nanda

medwireNews: Tofacitinib could soon be available in Europe for people with ankylosing spondylitis following a recommendation from the EMA to adopt a new indication for the drug.

According to the Committee for Medicinal Products for Human Use, the Janus kinase inhibitor is indicated for adult patients with active disease and an inadequate response to conventional treatment options.

This adds to the previous positive decisions for tofacitinib for the treatment of rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ulcerative colitis.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

ACR Convergence 2021 highlights

3–9 November: Keep up with the latest news and interviews from the conference.